Jeffrey S. Hackman, Chief Executive Officer and Director of Fennec Pharmaceuticals Inc., filed a Form 4 on November 2, 2026, reporting the acquisition of 1,159 common shares on October 31, 2026, at a price of $0, representing shares released from a prior restricted stock award.

Key Highlights

  • Reporting person: Jeffrey S. Hackman, CEO and Director of Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
  • Transaction date: October 31, 2026
  • Shares acquired: 1,159 common shares at a price of $0
  • Transaction code: A (acquisition), with shares released from restriction
  • Original award date: The shares were awarded on March 28, 2025, according to the filing
  • Beneficial ownership following transaction: 70,844 common shares held directly

Hackman's Restricted Share Release at Fennec Pharmaceuticals

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Jeffrey S. Hackman, who serves as both Chief Executive Officer and Director of Fennec Pharmaceuticals Inc., reported a change in his beneficial ownership of the company's common shares. The transaction, dated October 31, 2026, involved the acquisition of 1,159 common shares at a reported price of $0. The filing explains that these shares "represent shares released from restriction from shares awarded 3/28/2025."

The transaction code reported is "A," indicating an acquisition. No derivative securities transactions were reported in Table II of the filing. Hackman's total direct beneficial ownership of Fennec Pharmaceuticals common shares following the reported transaction stands at 70,844 shares, as disclosed in the filing. The form was signed by Jeffrey Hackman and filed on November 2, 2026.

The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934. No amendment date was listed, indicating this is an original filing. The reporting person filed as an individual rather than as part of a group, and the ownership form is reported as direct.

What Was Disclosed

Fennec Pharmaceuticals CEO and Director Jeffrey S. Hackman disclosed the release of 1,159 restricted common shares originally awarded on March 28, 2025, bringing his direct beneficial ownership to 70,844 common shares as of October 31, 2026.